Clinical research coordinator

The Institute for Value-Based Medicine® from The American Journal of Managed Care® hosts Innovating Cancer at the Frontier for Community and Rural Patients event in Kansas City

Retrieved on: 
Friday, November 17, 2023
HIPEC, Cancer, Patient, Frontier, Community, American Journal, Clinical research coordinator, Mobile phone

KANSAS CITY, MO, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The American Journal of Managed Care® (AJMC®), the leading multimedia peer-reviewed journal dedicated to issues in managed care, is proud to announce its upcoming Institute for Value-Based Medicine® event, Innovating Cancer at the Frontier for Community and Rural Patients.

Key Points: 
  • KANSAS CITY, MO, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The American Journal of Managed Care® (AJMC®), the leading multimedia peer-reviewed journal dedicated to issues in managed care, is proud to announce its upcoming Institute for Value-Based Medicine® event, Innovating Cancer at the Frontier for Community and Rural Patients.
  • This free in-person event will take place on Wednesday, Nov. 29 at iWerx in Kansas City, Missouri.
  • Attendees will hear from experts on the revolutionary cancer care that is on the frontier for the community and rural patients of Missouri.
  • In addition to the enriching content, attendees will have the opportunity to network and foster connections and collaborations that will drive positive change in the landscape of cancer care.

EQS-News: Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting

Retrieved on: 
Tuesday, October 17, 2023
Calcium, Neuroprotection, MS, Inflammation, Multiple sclerosis, Safety, Neurofilament, Magnetic resonance imaging, Biotechnology, Barrow Neurological Institute, Clinical research coordinator, RRMS, Research, Emphasis, MRI, AFL, PMS, Patient, Cleveland Clinic, Frankincense, Pharmaceutical industry, Short course immune induction therapy

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting

Key Points: 
  • Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting
    The issuer is solely responsible for the content of this announcement.
  • Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting
    – NfL Effect Consistent With Recently Released Data from Separate, Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis –
    NEW YORK, October 11, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced that Robert J.
  • EMPhASIS was an international, multicenter, double-blind, placebo-controlled, randomized, parallel-group trial, designed to assess the efficacy and safety of vidofludimus calcium in patients with RRMS.
  • On October 9, 2023, Immunic announced positive interim data from its phase 2 CALLIPER trial of vidofludimus calcium in patients with progressive multiple sclerosis (PMS).

Billboard Near Insurance Regulator Warns Against Brookfield’s Potential Takeover of American Equity Life Insurance, Citing UNITE HERE Report

Retrieved on: 
Wednesday, October 11, 2023
Commercial Building & Real Estate, Construction & Property, Professional Services, Insurance, Multimedia, BPY, NYSE, S&P Global, Acquisition, Business, Equity, Risk, Bermuda, AEL, UNITE, Brookfield Property Partners, Clinical research coordinator, Bloomberg, Airport, American National Insurance Company, ANAT, Life, Research, Sale, HERE, Financial services

UNITE HERE launched a billboard today warning customers of American Equity Investment Life Insurance Company (NYSE:AEL), that it may be purchased by the Bermuda-based affiliate of Brookfield (NYSE:BN).

Key Points: 
  • UNITE HERE launched a billboard today warning customers of American Equity Investment Life Insurance Company (NYSE:AEL), that it may be purchased by the Bermuda-based affiliate of Brookfield (NYSE:BN).
  • The billboard is located less than a mile from the Iowa Insurance Division, the state agency that would need to approve any sale of Des Moines-based American Equity.
  • View the full release here: https://www.businesswire.com/news/home/20231011402266/en/
    “Are you ready for Brookfield’s ‘office real estate apocalypse’?” the billboard asks.
  • The financial health of Brookfield’s commercial real estate holdings may be of interest to Iowa regulators and American Equity policyholders because of events following Brookfield’s acquisition of another life insurance company, American National (NASDAQ:ANAT).

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting

Retrieved on: 
Wednesday, October 11, 2023
Calcium, Neuroprotection, MS, Inflammation, Multiple sclerosis, Safety, Neurofilament, Magnetic resonance imaging, Barrow Neurological Institute, Clinical research coordinator, RRMS, Research, Emphasis, MRI, AFL, PMS, Observation, Patient, Cleveland Clinic, Pharmaceutical industry, Short course immune induction therapy

NEW YORK, Oct. 11, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced that Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, today presented data from the company's phase 2 EMPhASIS trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in relapsing-remitting multiple sclerosis (RRMS) at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting, taking place October 11-13 in Milan, Italy.

Key Points: 
  • Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, today presented data from the company's phase 2 EMPhASIS trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in relapsing-remitting multiple sclerosis (RRMS) at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting, taking place October 11-13 in Milan, Italy.
  • Dr. Fox has served as Coordinating Investigator in Immunic's multiple sclerosis (MS) programs and receives consulting fees for serving as an advisor to Immunic.
  • EMPhASIS was an international, multicenter, double-blind, placebo-controlled, randomized, parallel-group trial, designed to assess the efficacy and safety of vidofludimus calcium in patients with RRMS.
  • On October 9, 2023, Immunic announced positive interim data from its phase 2 CALLIPER trial of vidofludimus calcium in patients with progressive multiple sclerosis (PMS).

Recreation Therapy Study Proves Validity of Kayak Fishing for Veterans and First Responders

Retrieved on: 
Wednesday, August 23, 2023
Defense, Anxiety, Overalls, Water, HOW, Veteran, Clinical research coordinator, Doctor of Philosophy, Acute stress disorder, Family, Mental health, Nursing, Pharmaceutical industry

The study utilized a peer-reviewed, validated toolset of questions developed by the program’s Research Coordinator, Shelby Sharpe, PhD.

Key Points: 
  • The study utilized a peer-reviewed, validated toolset of questions developed by the program’s Research Coordinator, Shelby Sharpe, PhD.
  • Operation Early Impact proves the efficacy of HOW’s program through measuring rather than making assumptions.
  • We are expanding the study into a second phase that encompasses veterans, first responders, family members, care givers and health care professionals.
  • In addition to the Therapeutic Programs, HOW has volunteer-led chapters across the U.S. that hold monthly kayak fishing events at no cost.

New Study From Health Equity Platform Violet and Octave Reveals 145% in Unlocked Inclusive Care Ability And Increased Health Outcomes

Retrieved on: 
Tuesday, May 9, 2023
Benchmark, Workforce, Partnership, Gender identity, Octave, Health equity, Doctor of Philosophy, BIPOC, Clinical research coordinator, Disability, Nursing, Violet

Using this data, Octave matched diverse clients with providers, seeing an overall improvement in client retention and health outcomes.

Key Points: 
  • Using this data, Octave matched diverse clients with providers, seeing an overall improvement in client retention and health outcomes.
  • Because of their high standards of care and commitment to building health equity, Octave partnered with Violet to further amplify their efforts to support culturally diverse clients.
  • For this study, Violet benchmarked Octave providers’ inclusivity and tested care matching for clients requesting a diverse provider.
  • 145% more providers unlocked for inclusive care matching with Violet Benchmarks compared to diverse providers.

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

Retrieved on: 
Wednesday, February 22, 2023
CDW, Multiple sclerosis, Treatment, Clinical research coordinator, Safety, Barrow Neurological Institute, Patient, Emphasis, DHODH, OLE, Cleveland Clinic, Research, Great America Committee, MS, Pharmaceutical industry, RRMS, Short course immune induction therapy

NEW YORK, Feb. 22, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, will present data from the blinded and open-label extension (OLE) parts of the company's phase 2 EMPhASIS trial of lead asset, vidofludimus calcium (IMU-838), a selective oral DHODH inhibitor, in relapsing-remitting multiple sclerosis (RRMS) at the eighth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023, taking place February 23-25 in San Diego, California. Dr. Fox has served as Coordinating Investigator in Immunic's multiple sclerosis (MS) programs and receives consulting fees for serving as an advisor to Immunic.

Key Points: 
  • Dr. Fox has served as Coordinating Investigator in Immunic's multiple sclerosis (MS) programs and receives consulting fees for serving as an advisor to Immunic.
  • "We eagerly await reporting data from our ongoing phase 3 ENSURE program in relapsing MS as well as our ongoing phase 2 CALLIPER trial in progressive MS.
  • EMPhASIS is an international, multicenter, double-blind, placebo-controlled, randomized, parallel-group trial, designed to assess the efficacy and safety of vidofludimus calcium in patients with RRMS.
  • The trial included a 24-week blinded main treatment period testing 10, 30 and 45 mg of vidofludimus calcium and placebo.

EQS-News: Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

Retrieved on: 
Wednesday, February 22, 2023
CDW, Multiple sclerosis, Treatment, Clinical research coordinator, Safety, Barrow Neurological Institute, Patient, Emphasis, DHODH, OLE, Cleveland Clinic, Research, Great America Committee, MS, Pharmaceutical industry, RRMS, Short course immune induction therapy

Dr. Fox has served as Coordinating Investigator in Immunic’s multiple sclerosis (MS) programs and receives consulting fees for serving as an advisor to Immunic.

Key Points: 
  • Dr. Fox has served as Coordinating Investigator in Immunic’s multiple sclerosis (MS) programs and receives consulting fees for serving as an advisor to Immunic.
  • “We eagerly await reporting data from our ongoing phase 3 ENSURE program in relapsing MS as well as our ongoing phase 2 CALLIPER trial in progressive MS.
  • EMPhASIS is an international, multicenter, double-blind, placebo-controlled, randomized, parallel-group trial, designed to assess the efficacy and safety of vidofludimus calcium in patients with RRMS.
  • The trial included a 24-week blinded main treatment period testing 10, 30 and 45 mg of vidofludimus calcium and placebo.

D.A. Davidson Announces 2022 Equity Capital Markets Promotions

Retrieved on: 
Thursday, December 15, 2022
Banking, Asset Management, Professional Services, Finance, Clinical research coordinator, Creativity, Equity capital markets, Associate, Esther Clark Wright, Research, Investment banking, Culture, Financial institution, Professional, Partnership, Financial services, Holding company, Private investigator, Cement

Davidson & Co. announced today that 24 professionals across the Equity Capital Markets Group, including investment bankers and research analysts, earned promotions based on their exceptional contributions throughout 2022.

Key Points: 
  • Davidson & Co. announced today that 24 professionals across the Equity Capital Markets Group, including investment bankers and research analysts, earned promotions based on their exceptional contributions throughout 2022.
  • The Equity Capital Markets business consists of investment banking, institutional sales and trading, and equity research spanning four industries: Consumer , Diversified Industrials , Financial Institutions , and Technology .
  • Davidson, together with MCF Corporate Finance under its strategic partnership, works on origination and execution of transatlantic transactions under the brand D.A.
  • These individuals have contributed significantly to our culture and success as a firm over the past year and beyond, said Rory McKinney, President of Equity Capital Markets at D.A.

EQS-News: Evotec, CDP Venture Capital and Angelini Ventures launch translational partnership 'Extend' with leading Italian academic Institutions

Retrieved on: 
Friday, October 28, 2022
Transfer, Frankfurt Stock Exchange, Drug discovery, University, General manager, NASDAQ, Venture capital, Angelini, ISIN, Technology transfer, Efficiency, ESG, Mental health, CEO, Communication, Biomedical Research, Patient, Clinical research coordinator, Research, Twitter, Investment, Knowledge, Science, Partnership, Central nervous system, Innovation, Biotechnology, CDP Equity, LinkedIn, University of Milan, Growth, Wine, Economic development, Trematode life cycle stages, EVO, Leadership, Woman, Corporate venture capital, Therapy, MDAX, Pharma, Academy, Neurology, Industry, Quality of life, News, Security (finance), Cryptocurrency, Pharmaceutical industry, Risk management, Fine chemical, Management, Evotec

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the launch of Extend, a translational BRIDGE partnership in cooperation with CDP Venture Capital Sgr, a strategic pillar to Italy's economic growth and innovation, and Angelini Ventures, the Corporate Venture Capital arm of the multi-business industrial group Angelini Industries.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the launch of Extend, a translational BRIDGE partnership in cooperation with CDP Venture Capital Sgr, a strategic pillar to Italy's economic growth and innovation, and Angelini Ventures, the Corporate Venture Capital arm of the multi-business industrial group Angelini Industries.
  • Extend is a joint venture between Evotec, CDP Venture Capital and Angelini Ventures to develop translational drug discovery partnerships with highly renowned universities and research centres in Italy.
  • Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: We are excited to launch Extend together with our partners at CDP Venture Capital and Angelini Ventures.
  • Extend brings together leading academic institutions from Italy to accelerate their most promising assets towards commercialisation.